Aurobindo Pharma
-
Franchise India Bureau Aug 08 2019 - 1 min readAurobindo Pharma Ltd, the world’s 10th largest generics company, is eyeing rapid expansion in the US market, accounting for nearly half of the firm’s revenue. Hyderabad-headquartered company is betting big on the US market coupled with significant expansion in its injectables portfolio. N Govindrajan, MD, Aurobindo Pharma, said, “The US business contributed to 46 per ...
-
Franchise India Bureau Feb 12 2019 - 1 min readAurobindo Pharma, a world-leading marketer and manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, has completed the acquisition of Canadian generic pharma firm Apotex's commercial operations and certain supporting infrastructure in five European countries. The Hyderabad-headquartered drug maker, in July 2018, had inked a binding agreement to buy five of Apotex's European businesses, including infrastructure, personnel, ...
-
Franchise India Bureau Feb 11 2019 - 1 min readAurobindo Pharma Ltd has agreed to invest Rs 15 crore in exchange for a 19.9% stake in Synergy Remedies Pvt Ltd, a Tirupathi-based pharmaceutical company. The transaction will be providing Aurobindo access to supplies of active pharmaceutical ingredients (APIs) and intermediates from Synergy. Synergy was incorporated in 2011. It began commercial production in the financial year ...
-
Franchise India Bureau Nov 14 2018 - 0 min readAurobindo Pharma Ltd, a Hyderabad-based drugmaker, will acquire a product under development and related assets from Australia-based Advent Pharmaceuticals Pty Ltd for $12.5 million in cash. The deal is expected to close by January 2019. This acquisition will help Aurobindo to boost its research and development capabilities in complex speciality generics. Advent Pharmaceuticals is a ...
-
Franchise India Bureau Sep 06 2018 - 1 min readHyderabad-based Aurobindo pharma has acquired Sandoz Inc’s dermatology and oral solid business for $900 million in cash. Sandoz is a subsidiary of Swiss drug maker Novartis. The transaction will position Aurobindo as the second largest generic player in the US by prescriptions. It is expected to be completed by end of 2019. For Aurobindo, the deal ...